Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04391179 · ClinicalTrials.gov registry record · Phase 2
Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT04391179 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 99 participants.
The verdict
NCT04391179, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The most severe manifestations of COVID-19 include respiratory failure, coagulation problems, and death. Inflammation and blood clotting are believed to play an important role in these manifestations. Research in humans has shown that dipyridamole can reduce blood clotting. This research study is being conducted to learn whether 14 days of treatment with dipyridamole will reduce excessive blood clotting in COVID-19. This study will enroll participants with confirmed coronavirus (SARS-CoV)-2 infection that are admitted. Eligible participants will be randomized to receive dipyridamole or placebo for 14 days in the hospital. In addition, data will be collected from the medical record, and there will also be blood draws during the hospitalization.
Interventions
- DRUG Placebo oral tablet
- DRUG Dipyridamole 100 Milligram(mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2020-05-31 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04391179
The ClinicalTrials.gov registry entry for NCT04391179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04391179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04391179 about?
NCT04391179 is a clinical study titled "Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19". The most severe manifestations of COVID-19 include respiratory failure, coagulation problems, and death. Inflammation and blood clotting are believed to play an important role in these manifestations. Research in humans has shown that dipyridamole can reduce blood clotting. This research study is be...
What is the current status of trial NCT04391179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2020-05-31. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT04391179?
The interventions under investigation include: Placebo oral tablet (DRUG), Dipyridamole 100 Milligram(mg) (DRUG).
Who is sponsoring clinical trial NCT04391179?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.